Clinical trials: Transient Ischemic Attack (TIA)
Stroke, Cardiac Disease
Multifactorial Risk Stratification in Stroke Patients With Cardiac Disease
Prospective registry for multifactorial risk factor assessment, enrolling consecutive ischemic stroke/transient ischemic attack patients with structural, inflammatory, or arrhythmogenic cardiac disease, who are admitted to our…
- Trial name
- NCT04352790
- Volunteers
- 878 people
- Sponsor
- University Hospital Tuebingen
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer
Cryptogenic Transient Ischemic Attack and Minor Stroke
Predictors of Occult Atrial Fibrillation in 171 Patients With Cryptogenic TIA and Minor Stroke
Retrospective study, single-center, on 171 patients, presented a cryptogenic TIA and Minor stroke. This study objective is to determine profitability of Holter 21 days for screening paroxystic ACFA / flutter in cryptogenic…
- Trial name
- HOLTER-21J (NCT03166969)
- Testing
- Holter 21 days
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Versailles Hospital
Transient Ischemic Attacks, Minor Stroke
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
The primary goal of the research is to determine if 10 days of dual anti-platelet treatment is as effective as 30 days of similar treatment in the prevention of stroke, myocardial ischemia (MI) and death in patients with TIAs and…
- Trial name
- MENA-TIA (NCT02144831)
- Testing
- anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
- Where
- Canada
- Sponsor
- University of Alberta
Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases
Immunomodulatory Effects of PCSK9 Inhibition
Cardiovascular disease (CVD) represents the leading cause of death worldwide. While medications, such as statins, significantly reduce atherosclerotic CVD (ASCVD) risk by lowering low density lipoprotein levels, they may also…
- Conditions
- Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis, Arterial Inflammation
- Trial name
- INSPIRAR (NCT05720156)
- Testing
- 99mTc-tilmanocept SPECT/CT scanning
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Ischemic Stroke, Transient Ischemic Attack
Treat Stroke to Target
The aim of this study is the evaluation of two usual care strategies after stroke or TIA : achieved target LDL-C of 100 mg/dL (+/-10 mg/dL) or less than 70 mg/dL.
- Conditions
- Ischemic Stroke, Transient Ischemic Attack, Atherosclerotic Stenosis
- Trial name
- TST (NCT01252875)
- Testing
- Target : 100 mg/dL (+/-10 mg/dL), 70 mg/dL
- Where
- 2 sites in France
- Volunteers
- 2,873 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ischemic Stroke, Transient Ischemic Attack
AcoArt VI / Vertebral Artery Ostium Stenosis in China
The purpose of this study is to determine whether DEB is not inferior to common bare metal stent using under in long-term vessel patency and inhibiting restenosis in Vertebral Artery Ostium Stenosis
- Trial name
- NCT03910166
- Testing
- drug-coated balloon catheter（Orchid, Acotec）, Intracranial artery stent system（APOLLO）
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Acotec Scientific Co., Ltd